Heights Capital Bets $16M on ImmunityBio: A Calculated Gamble?

The purchase is stark. No hedging, no half-measures. Heights Capital, having liquidated other positions, has allocated a chunk of its $364.74 million portfolio to a company whose shares have plummeted 15.8% year-to-date. For context, the S&P 500 has fared 28.5 percentage points better. Yet the fund persists, as if betting on a horse with a broken leg and a jockey who’s never won a race.





